Results 1 to 10 of about 1,963 (123)

Development of immune radiotherapy with yttrium by targeting Frizzled homologue 10 (FZD10) in cervical cancer [PDF]

Gynecologic Oncology Reports
Objective: Radioimmunotherapy (RIT) is a combination of the therapeutic properties of radioisotopes and specific antibodies used to eliminate tumors.
Yuki Okuma, Yuji Ikeda, Osamu Kobayashi, Saki Kamata, Erina Matsuda, Takahiro Nakajima, Keisuke Saito, Naoko Tomita, Yoko Nakanishi, Yosuke Harada, Suyoun Chung, Jae-Hyun Park, Shinobu Masuda, Yusuke Nakamura, Kei Kawana   +14 more
doaj   +2 more sources

Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study [PDF]

Journal of Clinical Medicine, 2022
Neuroendocrine neoplasms (NENs) constitute a heterogenous group of tumors originating from neuroendocrine cells scattered throughout the body. Peptide Receptor Radionuclide Therapy (PRRT) is a treatment of choice of unresectable metastasized progressive and well-differentiated NENs. The aim of the study was to assess early bone marrow and kidney injury
Barbara Bober, Marek Saracyn, Kornelia Zaręba, Arkadiusz Lubas, Paweł Mazurkiewicz, Ewelina Wilińska, Grzegorz Kamiński   +6 more
openaire   +2 more sources

Feasibility Study for Irradiation Production of 90Y by 49-2 Pool Reactor

Journal of Isotopes, 2023
90Y is an ideal therapeutic radionuclide, and its labeled radiopharmaceuticals are widely used in the diagnosis and treatment of a variety of cancers.
ZUO Yajie;CHEN Xiaoliang;ZHANG Yu;ZHANG Weijian;WANG Shuo;CHEN Xiaoxian
doaj   +1 more source

Transarterial Selective Internal Radiation Therapy with Yttrium-90 for Liver Metastatic Urothelial Carcinoma of the Ureter as a Bridging Therapy to Immunotherapy: A Case Report with a 10-Year Follow-Up

Case Reports in Oncology, 2023
Primary transitional cell carcinoma of the ureter is a rare type of cancer with metastasis presented in approximately 25% at diagnosis. Due to its rarity and poor prognosis, the management of this neoplasm is still controversial, and the development of ...
Bruno Pagnin Schmid, Marcela Juliano Silva Cunha, Leonardo Guedes Moreira Valle, Francisco Leonardo Galastri, Breno Boueri Affonso, Priscila Mina Falsarella, Rafael Aliosha Kaliks Guendelmann, Rodrigo Gobbo Garcia, Felipe Nasser   +8 more
doaj   +1 more source

Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C)

BMC Gastroenterology, 2022
Introduction National Comprehensive Cancer Network HCC guidelines recommend Y90 to treat BCLC-C patients only in select cases given the development of systemic regimens.
Pulak Goswami, Oladapo R. Adeniran, Shelby K. Frantz, Lea Matsuoka, Liping Du, Ripal T. Gandhi, Zachary S. Collins, Marc R. Matrana, Michael Petroziello, Jayson S. Brower, Daniel Y. Sze, Andrew S. Kennedy, Jafar Golzarian, Eric A. Wang, Daniel B. Brown   +14 more
doaj   +1 more source

Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine

Frontiers in Molecular Biosciences, 2023
Targeting HER 2 for imaging and therapy in nuclear medicine has been used with a special emphasis on developing more powerful radiopharmaceuticals. Zirconium-89 plays an essential role in immune PET imaging so was used labeled with anti-HER2 antibody ...
Daniela Miladinova
doaj   +1 more source

Case Report: Vasculitis Triggered by SIRT in a Patient With Previously Untreated Cholangiocarcinoma

Frontiers in Oncology, 2021
Arising from the biliary tract, cholangiocarcinoma is a rare and aggressive epithelial cancer. According to the primary site, it can be further classified into intrahepatic, perihilar and distal types.
Antonia Stamatiou, Jeremy Jankovic, Petr Szturz, Francois Fasquelle, Rafael Duran, Rafael Duran, Niklaus Schaefer, Niklaus Schaefer, Antonella Diciolla, Antonia Digklia, Antonia Digklia   +10 more
doaj   +1 more source

Radioimmunotherapy: A novel treatment of non-Hodgkin lymphoma [PDF]

Archive of Oncology, 2010
90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab (Bexxar) are current choices for radioimmunotherapy (RIT) of patients with follicular rituximab-relapsed or refractory CD20+ follicular B-cell NHL.
Petrović Tomislav, Mihailović Jasna
doaj   +1 more source

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Frontiers in Medicine, 2022
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR)
Mengqi Shi, Mengqi Shi, Vivianne Jakobsson, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Pek-Lan Khong, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang, Jingjing Zhang, Jingjing Zhang   +15 more
doaj   +1 more source

Evaluation of the pharmacokinetics, dosimetry, and therapeutic efficacy for the α-particle-emitting transarterial radioembolization (αTARE) agent [225Ac]Ac-DOTA-TDA-Lipiodol® against hepatic tumors

EJNMMI Radiopharmacy and Chemistry, 2023
Background The liver is a common site for metastatic disease for a variety of cancers, including colorectal cancer. Both primary and secondary liver tumors are supplied through the hepatic artery while the healthy liver is supplied by the portal vein ...
Anders Josefsson, Angel G. Cortez, Harikrishnan Rajkumar, Joseph D. Latoche, Ambika P. Jaswal, Kathryn E. Day, Mohammadreza Zarisfi, Lora H. Rigatti, Ziyu Huang, Jessie R. Nedrow   +9 more
doaj   +1 more source